FDA Seeks Input on Teen Tobacco Snooping Survey Renewal
Published Date: 5/4/2026
Notice
Summary
The FDA wants your thoughts on continuing the National Youth Tobacco Survey, which checks how many young people use tobacco. This survey helps protect kids and teens by tracking tobacco habits and making smarter health rules. If you want to share your opinion, send your comments by July 6, 2026—no cost to you, just your voice!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Parents May Need to Return Consent Forms
If your child is in grades 6–12, parents or guardians may need to complete an active consent form for the National Youth Tobacco Survey. FDA estimates 3,500 parents will be asked to spend about 10 minutes each (total 595 hours) to return these forms for the 2027–2029 survey period.
Students Will Take a 45-Minute Digital Survey
Students in grades 6–12 will be asked to take an anonymous, web-based tobacco survey that takes about 45 minutes. FDA estimates 29,575 student questionnaire responses for 2027–2029, totaling about 22,181 hours of student response time.
Overall Respondent Burden Will Rise
For the 2027–2029 NYTS, FDA estimates the overall respondent burden increases by 1,108 hours and 4,313 responses compared with the prior period. FDA reports a total annual burden of 23,708 hours across all respondent types for this information collection.
No Direct Money Costs to Respondents
FDA states there are no capital costs or operating and maintenance costs associated with this information collection, so respondents will not face direct monetary charges. You are asked only to provide information or return consent forms by the July 6, 2026 comment date if you want to comment on the collection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-08602 — Investigative Hearing
A tragic UPS cargo plane crash in Louisville killed 14 people and injured many more, sparking a big public hearing on May 19-20, 2026. The hearing will dig into airplane safety, design rules, and how the FAA and Boeing handle safety issues. This affects airlines, manufacturers, and passengers, aiming to boost safety and prevent future accidents.
Next: 2026-08606 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and decide on grant applications related to aging, genetics, neurodegeneration, and pediatric critical care. These meetings are private to protect sensitive information and personal privacy. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve new costs or changes to the process.